Home News Malik Kahook, MD: Updates on SpyGlass Platform for Glaucoma Treatment back to News
minute read
New 6-month results from a first-in-human trial investigating the SpyGlass drug delivery platform indicated continued reductions in intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The data were highlighted in an oral presentation at the Glaucoma 360 New Horizons Forum in San Francisco on February 3.
Topics: Press Coverage
1675 North Aurora Court
F731
Aurora, CO 80045
Administration: 720-848-2500
Appointments: 720-848-2020
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
